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ABSTRACT: Anthracyclines are effective drugs in the treatment of various cancers, but their use comes with severe side effects.
The archetypal anthracycline drug, doxorubicin, displays two molecular modes of action: DNA double-strand break formation
(through topoisomerase IIα poisoning) and chromatin damage (via eviction of histones). These biological activities can be
modulated and toxic side effects can be reduced by separating these two modes of action through alteration of the aminoglycoside
moiety of doxorubicin. We herein report on the design, synthesis, and evaluation of a coherent set of configurational doxorubicin
analogues featuring all possible stereoisomers of the 1,2-amino-alcohol characteristic for the doxorubicin 3-amino-2,3-
dideoxyfucoside, each in nonsubstituted and N,N-dimethylated forms. The set of doxorubicin analogues was synthesized using
appropriately protected 2,3,6-dideoxy-3-amino glycosyl donors, equipped with an alkynylbenzoate anomeric leaving group, and the
doxorubicin aglycon acceptor. The majority of these glycosylations proceeded in a highly stereoselective manner to provide the
desired axial α-linkage. We show that both stereochemistry of the 3-amine carbon and N-substitution state are critical for
anthracycline cytotoxicity and generally improve cellular uptake. N,N-Dimethylepirubicin is identified as the most potent
anthracycline that does not induce DNA damage while remaining cytotoxic.
■ INTRODUCTION
The anthracycline drug doxorubicin (adriamycin, Figure 1A,
1a) is one of the most used anticancer drugs in history, and is
annually prescribed to over one million cancer patients.1 While
doxorubicin is effective against a wide variety of cancers,
including leukemia, non-Hodgkin’s lymphoma, and breast
cancer, its use is limited by severe side effects. Cardiotoxicity,
the main treatment-limiting side effect, emerges in a
cumulative manner, and for this reason treatment with
doxorubicin is restricted to a maximum of six to eight
treatment cycles.2 Thousands of analogues of doxorubicin
produced by (mutant) enzymes or prepared by organic (semi-
)synthesis, have been tested for their biological activities in the
past decades, with the aim to identify more effective
anthracyclines with limited side effects.3−5 However, only a
few of these anthracycline analogues have been approved for
use in clinical practices. The 4′-epimer of doxorubicin,
epirubicin (Figure 1A, 2a), is one of these clinically approved
doxorubicin variants, and has a higher cardiotoxic risk
threshold regarding its cumulative dose (for epirubicin, >720
mg/m2; for doxorubicin, >500 mg/m2).6 Currently, epirubicin
is used in the treatment of breast, ovarian, gastric, and lung
cancers, as well as several types of lymphomas.7 This illustrates
that new effective and less toxic anthracyclines can be
developed, which may allow more intense, longer, and more
effective treatment of cancer patients, with limited long-term
side effects for cancer survivors.
Deeper understanding of the molecular mode of action of
anthracycline drugs is key for the development of new and
improved (in terms of efficacy) analogues. One key feature of
doxorubicin is the formation of DNA double-strand breaks due
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to topoisomerase IIα poisoning.8,9 Doxorubicin inhibits
topoisomerase IIα after the generation of DNA double-strand
breaks and before re-ligation of DNA, thus resulting in DNA
damage. For decades, this mode of action was thought to be
the main mechanism for the remarkable anticancer activity of
doxorubicin and its structural analogues. However, aclarubicin
(Figure 1B), another anthracycline analogue used in Japan and
China, is at least equally effective in the treatment of acute
myeloid leukemia (AML), but does not produce such DNA
double-strand breaks.9 Moreover, aclarubicin is much less
cardiotoxic.10 Aclarubicin functions by a recently discovered
second activity of anthracyclines: eviction of histones from the
chromatin.9,11 These evicted histones are then replaced by new
nascent ones, resulting in epigenetic alterations.12 Further-
more, previous work from our labs showed that the
combination of histone eviction and DNA double-strand
break formation, as exerted by doxorubicin, is responsible for
the major side effects of this compound: cardiotoxicity and
secondary tumor formation.10 N,N-Dimethyldoxorubicin
(Figure 1A, 1b), a close doxorubicin analogue featuring the
dimethylamine characteristic for aclarubicin, mirrors the
biological activity of aclarubicin, by only inducing histone
eviction (and not DNA damage).10 Like aclarubicin, N,N-
dimethyldoxorubicin is an effective anticancer agent that lacks
the severe side effects displayed by doxorubicin in various
mouse models.10 These data suggest that separating DNA from
chromatin damage activities, as found in the anthracyclines
currently used in the clinic, results in drugs lacking the major
long-term side effects. In addition, chromatin damage appeared
to be the major cause for the anticancer activity of these
compounds. Our follow-up studies on a series of doxorubicin/
aclarubicin hybrid structures, varying in the tetracyclic aglycon,
the sugar moiety (from the doxorubicin monosaccharide up to
the aclarubicin trisaccharide), and the N-alkylation pattern
revealed that dimethylated structures fail to induce DNA
double-strand breaks while remaining cytotoxic.13 These
findings raise the question whether there is a structure−
activity relationship for stereoisomeric analogues of doxor-
ubicin, and whether this may lead to potential new effective
anticancer drugs. To this end, we herein report the synthesis
and evaluation of a coherent, focused library of diastereomers
of doxorubicin (1a) in the 1,2-amino alcohol arrangement of
the 3-amino-2,3-dideoxy-L-fucoside (daunosamine) character-
istic for this compound. Compounds 1a/b, 2a/b, 3a/b, 4a/b
featuring both the free amine and the N,N-dimethylated, some
of which have been reported previously10,14,15 have been
generated. Our general synthesis route for the preparation of
these compounds is based on the use of gold-catalyzed
glycosylation reactions of alkynylbenzoate (ABz) donors. Most
of these proceed with excellent stereoselectivity, which we
propose to be rooted in the oxocarbenium ion-like
intermediates formed in these reactions. Subsequently, we
evaluated the biological activities of the set of anthracyclines by
testing their abilities to induce DNA damage and histone
eviction, their cellular uptake, and their cytotoxicity. Com-
pounds featuring an equatorially oriented, dimethylated sugar
Figure 1. (A) Chemical structures of doxorubicin (1a) and derivatives (1b, 2b, 3b, 4b), differing in stereochemistry and N,N-dimethylation on the
sugar moiety. (B) Chemical structure of aclarubicin.
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amine proved to be the most cytotoxic and in general are also
taken up best by cells. From these, N,N-dimethylepirubicin
(2b) was identified (next to the previously described N,N-
dimethyldoxorubicin (1b)) as the most potent anthracycline in
this coherent set of epimeric doxorubicin analogues, with an
excellent cytotoxicity profile and no DNA double-strand break
activity.
■ RESULTS AND DISCUSSION
Synthesis of the Set of (N,N-Dimethyl)doxorubicin
Stereoisomers. We started with the development of a
synthetic methodology to prepare the focused library depicted
in Figure 1 (compounds 2b, 3a/b, 4a/b). Recently, we
reported the synthesis of N,N-dimethyldoxorubicin (1b),10
whereas doxorubicin (1a) and epirubicin (2a) are both
commercially available. Our synthetic method is based on
gold(I)-mediated glycosylation chemistry, developed by Yu
and co-workers,16 that in our hands has proven effective in the
creation of the anthracycline α-fucosidic linkages.13,17 In the
assembly of doxorubicin/aclarubicin hybrids, we found that the
use of an allyloxycarbamate (Alloc) to mask the amino group
of the 2,3-dideoxy-3-aminofucose in combination with
relatively labile silyl ethers to protect the hydroxyl groups is
very effective for the assembly of the anthracycline targets.13
Thus, alkynylbenzoate donors 9, 12, and 16 were designed and
assembled as depicted in Scheme 1. p-Methoxyphenolates 6
and 10 were prepared from precursor 518 (a mixture of 33:67
R/S at C3) by treatment with p-methoxyphenol in the
presence of catalytic trimethylsilyl trifluoromethanesulfonate
(TMSOTf) to give equatorial azide 6 in 50% yield and axial
azide 10 in 7%. Deacylation under Zempleń conditions was
followed by triethylsilylation of the resultant alcohol. Then, the
azide was reduced under Staudinger conditions and converted
to the allyloxycarbamate to give 7 and 11. The p-
methoxyphenolates were then subjected to oxidative hydrolysis
of the anomeric p-methoxyphenolate using Ag(DPAH)2,
19
delivering the lactols, which were transformed into the
required alkynylbenzoates (ABz) by a Steglich esterification
with o-cyclopropylethynylbenzoic acid (8),20 providing donor
glycosides 9 and 12.
In preparing for the synthesis of the 3-epi-daunosamine
donor 16, acetate 1321 was converted to the p-methoxyphe-
nolate by the action of BF3·OEt2 giving, after deacylation,
compound 14. Triethylsilylation of the 4-hydroxyl and
conversion of the azide into the allyloxycarbamate yielded
15. Removal of the anomeric p-methoxyphenol group and
installation of the alkynylbenzoate was then achieved as
described for donors 9 and 12 to give donor 16. The three
alkynylbenzoate donors 9, 12, and 16 were used, alongside
daunosamine donor 17 that we previously assembled,13 in
glycosylation reactions toward doxorubicin analogues 2b−3a/
b−4a/b (Scheme 2). Treatment of a mixture of donor 9 and
protected doxorubicinone acceptor 1822 with a catalytic
amount of PPh3AuNTf2 in DCM at room temperature led to
the formation of anthracycline 19 in 80% yield as an 8:1 α/β-
mixture. The desired α-anomer could be readily separated to
provide the desired axially linked 19. The analogous
glycosylation of 12 and 18 proceeded with poor stereo-
selectivity and provided 20 as a 1.5:1 α/β mixture in 50% yield.
The condensation of donor 16, having two axial substituents at
C-3 and C-4, led to the formation of the protected doxorubicin
analogue 21 with excellent stereoselectivity and the desired
product was obtained as a single anomer in 56% yield. The
Scheme 1. Synthesis of Aminosugar Alkynylbenzoate Donors 9, 12, and 16a
aReagents and conditions: (a) p-methoxyphenol, TMSOTf, dichloromethane (DCM), 0 °C, 50% for 6, 7% for 10; (b) (i) p-methoxyphenol, BF3·
OEt2, DCM, −60 to −40 °C; (ii) NaOMe, MeOH, 70% over two steps; (c) (i) NaOMe, MeOH; (ii) TESOTf, pyr., DCM, 95% over two steps
from 6, quant. over two steps from 10; (d) (i) polymer-bound PPh3, tetrahydrofuran (THF), H2O; (ii) allyl chloroformate, pyr., DCM, quant. over
two steps for 7; quant. over two steps for 11; quant. over two steps for 15; (e) TESOTf, pyr., quant.; (f) (i) silver(II) di(hydrogen dipicolinate)
hydrate, NaOAc, MeCN, H2O, 0 °C; (ii) ethylcarbodiimide hydrochloride (EDCI·HCl), 4-dimethylaminopyridine (DMAP), N,N-
diisopropylethylamine (DIPEA), DCM, 49% over two steps for 9 (β-anomer only), 57% over two steps for 12 (β-anomer only), 79% over two
steps for 16 (1:3 α/β).
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glycosylation of daunosamine donor 17 and acceptor 18 also
delivered the desired α-anomer with excellent stereoselectivity,
forming 22 in 56% yield.
We propose that the observed stereoselectivityor lack
thereofin these glycosylations can be understood upon
perusal of the intermediate oxocarbenium ions (or oxocarbe-
nium ion-like species), their conformational behavior, and the
direction nucleophiles may take toward forming a glycosidic
linkage. The dideoxy nature of the used donors makes them
relatively reactive (“armed”), and the anomeric cation thus
readily forms upon activation of the alkynylbenzoate anomeric
leaving group.23 First-order nucleophilic substitution (SN1)-
like pathways are further promoted by the use of the non-
nucleophilic counterion triflimide (NTf2).
24 The intermediate
oxocarbenium ion can adopt different conformations (often
close to half-chair structures) and preferred conformations are
the result of stereoelectronic effects as exerted by the
substituents on the ring.25 Electronegative atoms (such as
oxygen and nitrogen) prefer to adopt an axial orientation when
mounted at C-3 or C-4. Alkyl groups will preferentially adopt a
pseudo-equatorial orientation for steric reasons.25−27 In
addition, an incoming nucleophile, which will preferentially
attack this oxocarbenium ion from the β-face (to deliver the
product through a favorable chairlike transition state), will
experience 1,3-diaxial interactions with the substituent at C-3
as well as the C-6 methyl group. Therefore, the incoming
doxorubicinone nucleophile will preferentially attack the all-
equatorial 3H4 conformer of 9, leading to the formation of the
α-product in good selectivity (Scheme 3A). The 3H4 and
4H3
half-chair oxocarbenium ions emerge from activating donor 12
each place one of the electronegative substituents in an axial
position and will therefore be of comparable stability (Scheme
3B). The trajectories of incoming nucleophiles on these ions
will experience similar steric interactions, explaining the poor
selectivity observed in the glycosylation of donor 12 and
acceptor 18. Zeng et al. have previously reported that
glycosylations of similar ristosaminyl alkynylbenzoate donors
to various glycosyl acceptors proceeded with comparably poor
selectivity.28 The excellent stereoselectivity of donor 16 can be
traced back to the 3H4 half-chair oxocarbenium ion, which
Scheme 2. Synthesis of (N,N-Dimethyl)doxorubicins 2b−3a/b−4a/ba
a(a) 10 mol% PPh3AuNTf2, DCM, 80% for 19 (8:1 α/β); 50% for 20 (1.5:1 α/β); 56% for 21 (>20:1 α/β), 56% for 22 (>20:1 α/β); (b)
Pd(PPh3)4, NDMBA, DCM; (c) NaBH(OAc)3, aqueous (aq.) CH2O, EtOH, 61% over two steps from 19; (d) HF·pyr., pyr., 0 °C, quant. for 2b;
35% over three steps for 4b; 61% over two steps for 3a, 48% over three steps for 3b; (e) lyophilization from aq. HCl, 54% over three steps.
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places both the C-3 and C-4 electronegative groups in an axial
position, while having the C-6-methyl oriented equatorially
(Scheme 3C). Finally, the 3H4 half-chair oxocarbenium ion
generated from donor 17 puts just the C-3 substituent in a
favorable axial position (Scheme 3D). However, the incoming
nucleophile would suffer 1,3-diaxial interactions with the C-3
and C-6 substituents in the 4H3 oxocarbenium ion con-
formation. This together accounts for the high stereoselectivity
found for the glycosylation found between donor 17 and
acceptor 18.
Alloc removal of 20 and subsequent desilylation delivered
4a, which was turned into its HCl salt for solubility. Reductive
Scheme 3. Mechanistic Rationale for the Stereoselectivity Found in the Glycosylations of Donors 9, 12, 16, and 17 with
Acceptor 18a
aThe equilibria between the 3H4 and
4H3 conformers of the oxocarbenium ions are indicated. The bold arrows indicate the most favorable product
forming pathways. Nu = acceptor 18.
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amination of the amine formed upon Alloc removal from 20
and desilylation delivered 4b. Using a similar sequence of
reactions, 21 was transformed into 3a and 3b. Of note, NMR
analysis of compound 4b indicated that the sugar ring adopts a
4C1 conformation, rather than the
1C4 conformation, taken up
by its nonmethylated counterpart 4a (see Figure S4 for
annotated NMR spectra). The observed conformation of the L-
megosamine sugar moiety in 4b is consistent with that found
in the macrolide megalomycin.29 As a result, the tertiary amine
in 4b points away from the aglycone, and the overall shape of
anthracycline 4b differs significantly from the other generated
compounds.
DNA Damage Capacity and Histone Evicting Prop-
erty of the (N,N-Dimethyl)doxorubicin Stereoisomers.
Doxorubicin and its analogues used in the clinic have two main
activities: DNA damage and chromatin damage.9,10 Dimethy-
lation of the amine can separate these activities, but sugar
epimers of doxorubicin have not been evaluated for this.
Therefore, we evaluated our panel of (N,N-dimethyl)-
doxorubicin isomers for these biological activities. DNA
double-strand break formation by the various compounds
was determined indirectly by visualization of γH2AX (a post-
translational modification on histone H2A that occurs as part
of the DNA damage response) by Western blot analysis
(Figure 2A,B).30 In addition, the degree of DNA breaks was
assessed more directly using constant-field gel electrophoresis
(CFGE, Figure 2C,D).
The four anthracyclines bearing a free amine in their sugar,
being doxorubicin (1a), epirubicin (2a), 3′-epi-doxorubicin
(3a), and 3′,4′-epi-doxorubicin (4a), induced DNA breaks. For
the analogues featuring a tertiary amine, DNA double-strand
break formation was absent or reduced, compared to their
primary amine counterparts. Dimethyldoxorubicin (1b) and
dimethyl-epi-doxorubicin (2b) induced (almost) no DNA
breaks, yet N,N-dimethyl-3′-epi-doxorubicin (3b) and N,N-
dimethyl-3′,4′-epi-doxorubicin (4b) did produce DNA breaks,
although significantly less so than their nonmethylated
counterparts (Figure 2B,D). Overall, the orientation of the 4-
OH function (1a vs 2a, 1b vs 2b, 3a vs 4a, 3b vs 4b) had little
effect on their DNA damaging activity.
Since our previous findings indicate that chromatin damage,
rather than DNA damage, is the most dominant cytotoxic
mechanism of tumor killing by anthracycline drugs,10,12 we
investigated the ability of our panel of compounds (1a/b, 2a/
b, 3a/b, 4a/b) to induce histone eviction. To do so, part of the
nucleus of MelJuSo cells stably expressing PAGFP-H2A was
photoactivated, and release of these fluorescent histones was
followed over time upon treatment with the different
compounds (Figures 3A and S1). In all cases, the N,N-
dimethylated variants (1b, 2b, 3b, and 4b) were more potent
in evicting histones than their free amine counterparts (Figure
3A). Of the dimethylated compounds, N,N-dimethyl-3′-
epidoxorubicin (3b) showed the lowest histone evicting
activity, with 3′-epidoxorubicin (3a) being the only compound
that failed to evict histones.
Subsequently, the cytotoxicity of the compounds was
determined in a panel of 14 different tumor cell lines in
vitro (Figures 3B,C and S2). With the exception of compound
3b, all compounds with tertiary amines have a lower IC50 value
in the tested tumor cell lines than their nonmethylated
counterparts. Furthermore, the compounds with the amine in
an equatorial position (1a/b, 2a/b, and 4b) are effective at
killing most of the cell lines, down to nanomolar concen-
trations, while the compounds with the amine in axial
configuration (3a/b, 4a) show poor cytotoxicity. The differ-
ence in cytotoxicity between 3a versus 4a, and 3b versus 4b is
Figure 2. DNA damage formation by the (N,N-dimethyl)doxorubicin stereoisomers (1a/b, 2a/b, 3a/b, 4a/b). K562 cells were treated for 2 h with
10 μM of the indicated compounds, and etoposide (10 μM) was used as a positive control. (A) DNA double-strand breaks were measured
indirectly by visualization of the γH2AX levels by Western blot. Actin was used as a loading control, and molecular weight markers are indicated.
(B) Quantification of the γH2AX signal normalized to actin, and relative to etoposide. Results are presented as mean ± standard deviation (SD) of
three independent experiments. Ordinary one-way analysis of variance (ANOVA); *P < 0.05, **P < 0.01, ***P < 0.001. (C) DNA break formation
by the various compounds was directly analyzed by CFGE. The position of intact and broken DNA is indicated. (D) Quantification of the fraction
of broken DNA relative to etoposide. Results are presented as mean ± SD of four independent experiments. Ordinary one-way ANOVA; ****P <
0.0001.
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remarkable. 3′-epi-Doxorubicin 3a and 3′,4′-epi-doxorubicin 4a
both show poor cytotoxicity, and the dimethylated variant of
3a, compound 3b, is not more effective, while the dimethylated
variant of 4a, being 4b, is significantly more cytotoxic (Figure
3C). Possibly, this is due to the fact that the sugar in N,N-
dimethylated 4b exists in a different conformation than in 4a,
placing the C-3 dimethylamino group in an equatorial
orientation (similarly to 1a/b and 2a/b), pointing away from
the aglycone rather than toward it (as for compounds 3a/b and
4a, Figure S4).
Another critical factor for the effectiveness of drugs is their
ability to enter the cell. Since all variants in our library are
fluorescent, this could be determined by flow cytometry. K562
and MeIJuSo cells were treated with compounds 1a/b, 2a/b,
3a/b, 4a/b and intracellular fluorescence was measured 2 h
post treatment (Figure 4A,B). Compounds 1b, 2b, and 4b all
featuring the N,N-dimethyl moiety are taken up much more
efficiently than the corresponding primary amines, 1a, 2a, and
4a, respectively. This was not the case for 3a, which was taken
up more efficiently than the other primary amine epimers. The
difference in uptake with its dimethylated variant 3b is small.
Overall, it can be concluded that the cytotoxicity of the here
studied anthracyclines is mainly determined by their histone
eviction effectivity (Figures 4C and S3A), which strongly
correlates to the rate of uptake of the compounds (Figure
4A,B). Compounds featuring an N,N-dimethyl moiety are
more effective histone evictors (Figure 4D) and are therefore
more cytotoxic than the corresponding compounds having a
primary amine. The orientation of the OH group at the 4′
position has very little effect on cytotoxicity (Figure S3A,B).
Additionally, the stereochemistry of the fucose-carbon (C-3)
bearing the amine functionality has a major influence on the
IC50 values of the compounds in vitro. Compounds featuring
an equatorial (or outward facing, in the case of 4b) amine are
the most effective (1a/b, 2a/b, and 4b; Figure 4E).
■ CONCLUSIONS
Despite the widespread use of doxorubicin for the treatment of
various cancers for nearly 5 decades, its structure−activity
relationship is still not fully understood. Although doxorubicin
Figure 3. Chromatin damage capacity and cytotoxicity of epimeric (N,N-dimethyl)doxorubicin analogues. (A) Quantification of histone eviction
measured as PAGFP-H2A release from photoactivated nuclear regions after administration of 10 μM of the indicated doxorubicin isomers (in
colors on right). Ordinary two-way ANOVA, Turkey’s multiple comparison test; ****P < 0.0001. (B) Cytotoxicity of 1a/b, 2a/b, 3a/b, 4a/b in
A549 and FM3 cells. Cells were treated for 2 h with different concentrations of the indicated isomers followed by drug removal. Cell survival was
determined 72 h post drug removal using CellTiter Blue. Colors correspond to the drugs shown in (A). Data are shown as mean ± SD from four
independent experiments. (C) Color code table depicting the IC50 for compounds 1a/b, 2a/b, 3a/b, 4a/b determined for the 14 tumor cell lines
tested. Red (high IC50 = low cytotoxicity) to yellow (medium IC50) to green (low IC50 = high cytotoxicity). IC50 for 4a vs 4b: Ordinary two-way
ANOVA with Sidak’s multiple comparison test; ****P < 0.0001.
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is a very effective anticancer drug, its use is limited by
cumulative cardiotoxicity and treatment-related secondary
tumors. Chromatin damage by eviction of histones is a new
mode of action of anthracyclines,9 which brings renewed
interest to develop new doxorubicin analogues. We showed
that the anthracyclines, N,N-dimethyldoxorubicin (2b) and
aclarubicin, are unable to generate DNA breaks, yet induce
chromatin damage via eviction of histones.10 These analogues
remain equally potent to doxorubicin, but without the
induction of cardiotoxicity and secondary tumor formation.
Here, we synthesized a focused library of stereoisomers with
respect to the 1,2-amino-alcohol characteristic for the daunos-
amine sugar within doxorubicin and the four possible
stereoisomers both as primary and tertiary (dimethylated)
amines. The set of doxorubicin analogues were obtained by
glycosylating the doxorubicin aglycon with suitably protected
alkynylbenzoate donors. The focused library was evaluated for
histone eviction activity and DNA double-strand cleavage
capacity. The doxorubicin isomers with the amine positioned
axially show poor histone eviction activity and display limited
cytotoxicity compared to their equatorial amine counterparts.
The exception to this is 4b, in which the sugar moiety has
shown to undergo a ring-flip in solution. Possibly, this
configuration, having an outward-facing amine as a result of
this conformational change, causes the observed activities.
Remarkably, the N,N-dimethylated variants showed strongly
improved cellular uptake, some up to 10-fold, compared to
their nonmethylated counterparts. How anthracyclines are
taken up by cells is unclear, but the N,N-dimethylation likely
increases the basicity of the amine, as well as the log P, both of
which could influence diffusion through the cell membrane.
The rate of histone eviction correlates strongly with the cellular
uptake, which influences their cytotoxicity. Further chemical
modifications of anthracyclines aimed at improving cellular
uptake will help in achieving cytotoxicity at lower concen-
trations.
We have previously shown that N,N-dimethyldoxorubicin
(1b) completely abolishes DNA double-strand break for-
mation while not affecting the ability to kill tumor cells,
compared to doxorubicin (1a), which does induce DNA
damage.10 This appears to be a general theme, as N,N-
dimethylepirubicin (2b) also lacks DNA damage capacity and
is more cytotoxic than epirubicin (2a). Because N,N-
dimethylepirubicin (2b) displays potent antitumor activity in
vitro, it makes us believe this compound could be an attractive
lead for further development toward new, possibly more
effective anthracyclines. More generally, we feel our results,
based on the synthesis and evaluation of this focused library of
close structural and stereochemical analogues, warrant the
assessment of more such compound collections. These would
Figure 4. Structure−function relationship of our library of (N,N-dimethyl)doxorubicin isomers. (A, B) Uptake of the different isomers 2 h post
treatment with 1 μM of the indicated compound for K562 (A) and MelJuSo (B) cells. Relative fluorescence to the parental compound doxorubicin
is plotted for K562 and MelJuSo cells. Data are shown as mean ± SD. (C) Histone eviction speed (the time at which 25% of the initial signal is
reduced) is correlated with IC50 of the various doxorubicin isomers. (D) N,N-Dimethylation of the sugar of the analogues enhances the histone
eviction speed. (E) Equatorial positioning of the amine improves the cytotoxicity of the doxorubicin analogues. Two-tailed Pearson r correlation *p
< 0.05, **p < 0.01.
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feature, for instance, selected variations in the aglycon, in the
sugar part (instead of stereoisomers as presented here also
regio-isomers and/or glycosylated derivatives) and in the
nature of the amine (next to methylation also other alkyl
substituents). Thus, evaluating the chemical space around old
anticancer drugs can detect new activities and improve these
drugs, as illustrated by this study.
■ EXPERIMENTAL SECTION
Materials and Methods for Biological Evaluation. Chemicals.
Doxorubicin and epirubicin were purchased from Accord Healthcare
Limited, U.K., and etoposide was purchased from Pharmachemie, NL.
Cell Culture. K562 cells (B. Pang, Stanford University), HCT116
cells (T. van Hall, LUMC, The Netherlands), BXPC-3 cells (ATCC
CRL-1687), PC3, and DU145 cells (C. Robson, Newcastle
University, U.K.) were maintained in Roswell Park Memorial Institute
(RPMI)-1640 medium supplemented with 8% fetal calf serum (FCS).
A549 cells (R. Bernards, NKI, The Netherlands), FM3 cells (D.
Peeper, NKI, The Netherlands), U87 MG (ATCC HTB-14), U118
MG (ATCC HTB-15), U2Os cells (ATCC HTB-96), Hela cells
(ATCC CCL-2), and SKBR3 (R. Beijersbergen, NKI, The Nether-
lands) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 8% FCS. BT474 cells (R. Beijersbergen,
NKI, The Netherlands) were maintained in DMEM/F12 medium
supplemented with 8% FCS. MelJuSo cells were maintained in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with
8% FCS. MelJuSo cells stably expressing PAGFP-H2A were
maintained in IMDM supplemented with 8% FCS and G-418, as
described. Cell lines were maintained in a humidified atmosphere of
5% CO2 at 37 °C and regularly tested for the absence of mycoplasma.
Western Blot and Constant-Field Gel Electrophoresis (CFGE).
Cells were treated with drugs at indicated dose for 2 h. Subsequently,
the drugs were removed by extensive washing and the cells were
collected and processed immediately for the assays. The cells were
lysed directly in sodium dodecyl sulfate (SDS) sample buffer (2%
SDS, 10% glycerol, 5% β-mercaptoethanol, 60 mM Tris−HCl pH 6.8,
and 0.01% bromophenol blue). Lysates were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) followed by Western
blotting. Primary antibodies used for blotting: γH2AX (1:1000, 05-
036, Millipore), β-actin (1:10 000, A5441, Sigma). DNA double-
strand breaks were quantified by constant-field gel electrophoresis as
described.31 Images were quantified using ImageJ software.
Microscopy. PAGFP-H2A photoactivation and time-lapse confocal
imaging were performed as described9 on a Leica SP8 confocal
microscope system, 63× lens, equipped with a climate chamber. Loss
of fluorescence after different treatments was quantified using ImageJ
software.
Cell Viability Assay. Cells were seeded into 96-well plates. Twenty-
four hours after seeding, the cells were treated with indicated drugs
for 2 h. Subsequently, the drugs were removed by extensive washing
and cultured for an additional 72 h. Cell viability was measured using
a CellTiter Blue viability assay (Promega). Relative survival was
normalized to the untreated control and corrected for background
signal.
Flow Cytometry for Measuring Drug Uptake in Cells. Cells were
treated with 1 μM of the indicated compounds for 2 h. Samples were
washed, collected, and fixed with paraformaldehyde. The samples
were analyzed by flow cytometry using BD FACS Aria II, with a 561
nm laser and a 610/20 nm detector. Data were analyzed using FlowJo
software.
Quantification and Statistical Analysis. Each experiment was
assayed in triplicate, unless stated otherwise. All error bars denote SD.
Statistical analyses were performed using Prism 8 software (Graph-
Pad, Inc.). Two-tailed Pearson analysis was used to determine
correlations, ns, not significant, *p < 0.05, **p < 0.01.
Experimental Details on the Synthesis of 2b−3a/b−4a/b. All
reactions were carried out in oven-dried glassware under a nitrogen
atmosphere, unless indicated otherwise. Chemicals were obtained
from commercial sources and were used as received. Reactions
involving HF·pyridine were carried out in high-density polyethylene
(HDPE) tubes. Solvents used in reactions were dried on molecular
sieves 4 or 3 Å. Reaction progress was monitored by thin-layer
chromatography (TLC) on Merck F254 silica TLC plates visualized by
254 or 365 nm UV light and/or spraying with Hanessian’s stain
(prepared by dissolving (NH4)6Mo7O24·4H2O (25 g/L) and
(NH4)Ce(SO4)4·2H2O (10 g/L) in 10% aq. H2SO4). Column
chromatography was carried out on silica gel (60 Å, 40−63 μm),
obtained from screening devices BV. Neutralized silica gel was
prepared by portion-wise suspending of silica gel (500 g) in H2O (1.7
L) containing NH4OH (25% solution, 100 mL), stirring for 30 min,
filtering off, and drying the residue at 150 °C. Toluene, MeOH, and
DCM were distilled prior to use in small-scale column chromatog-
raphy (<0.5 mmol) and size-exclusion chromatography. Size-exclusion
chromatography was carried out on a Sephadex LH-20 using a 1:1
MeOH/DCM mixture for elution. NMR spectra were recorded on a
Bruker AV-400, AV-500, or AV-600 NMR spectrometer. Chemical
shifts (d) are reported in parts per million (ppm), relative to
tetramethylsilane (TMS) or residual solvent signals. Peaks were
assigned using correlation spectroscopy (COSY) and heteronuclear
single quantum coherence spectroscopy (HSQC). High-resolution
mass spectrometry (HRMS) spectra were measured on a Waters
Synapt G2-Si time-of-flight (TOF) mass spectrometer using an
electrospray ion source (ESI) in positive mode (source voltage, 3.5
kV) and an internal lock mass LeuEnk [M + H]+ = 556.2771. Final
compounds were lyophilized from 10% aqueous pyridine (v/v).
Hydrochloride salts of final compounds were obtained by
lyophilization of the free bases from aq. HCl (10−3 M, 1 mL/μmol,
2 equiv).
General Procedure A: Oxidative Hydrolysis of p-Methoxyphenyl
Glycosides. To a solution of the glycoside in MeCN/H2O (0.03 M,
1:1 v/v) were added NaOAc (10 equiv) and Ag(DPAH)2·H2O (2.5
equiv). The reaction mixture was stirred for 1 h, diluted with sat. aq.
NaHCO3, and extracted thrice with DCM. Combined organics were
dried over MgSO4, and solvent was removed in vacuo. Column
chromatography gave the crude hemiacetals.
General Procedure B: Steglich Esterification with o-Cyclo-
propylbenzoic Acid. To a solution of the hemiacetal in DCM (0.1
M) were added DIPEA (9 equiv), DMAP (1 equiv), EDCI·HCl (3.5
equiv), and freshly prepared o-cyclopropylethynylbenzoic acid (8) (3
equiv). After consumption of the starting hemiacetal, the mixture was
diluted with DCM and washed with sat. aq. NaHCO3 and brine, dried
over MgSO4, and concentrated in vacuo. Column chromatography
gave the corresponding anomeric alkynylbenzoates.
General Procedure C: Glycosylation of Alkynylbenzoate Donors.
To a solution of the alkynylbenzoate donor and 14-O-tert-
butyldimethylsilyl-doxorubicinone (18) (1.5 equiv) in DCM (0.05
M) were added activated molecular sieves (4 Å), and the mixture was
stirred for 30 min. Subsequently, a freshly prepared 0.1 M DCM
solution of PPh3AuNTf2 (prepared by stirring 1:1 PPh3AuCl and
AgNTf2 in DCM for 30 min) (0.1 equiv) in DCM was added
dropwise. After stirring 30 min, the mixture was filtered and
concentrated in vacuo. Column chromatography gave the desired
anthracyclines.
General Procedure D: Global Desilylation. A solution of the
amine in pyridine (0.01−0.05 M) was cooled to 0 °C. HF·pyridine
(70 wt % HF, ± 3.8 mL/mmol starting material, 146 equiv) was
added, and the reaction mixture was stirred for 1−5 h at this
temperature. Solid NaHCO3 was added to quench, and the mixture
was stirred until cessation of effervescence. Salts were then filtered off,
and the filtrate was diluted with DCM (10 volumes), washed with
H2O, dried over Na2SO4, and concentrated in vacuo. Column
chromatography on neutralized silica gel gave the deprotected
anthracyclines.
p-Methoxyphenyl-4-O-acetyl-3-azido-2,3-dideoxy-α-L-rhamnopyra-
noside (6) and p-Methoxyphenyl-3-azido-4-O-acetyl-2,3,6-tri-
deoxy-β-l-ribohexapyranoside (10): A mixture of acetates 5 (24.8
g, 96.4 mmol) and p-methoxyphenol (12.6 g, 101 mmol, 1.05 equiv)
was coevaporated thrice with toluene and subsequently dissolved in
DCM (480 mL). Activated 4 Å molecular sieves were added, and the
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mixture was allowed to stir for 30 min. Thereafter, TMSOTf (1.70
mL, 9.6 mmol, 0.1 equiv) was added at 0 °C and the mixture was
stirred for a further 3 h at that temperature. It was then filtered into
sat. aq. NaHCO3, after which the organic layer was separated, washed
with brine, dried over MgSO4, and concentrated in vacuo. Column
chromatography (7:93 EtOAc/pentane) gave compound 6 as a white
solid (11.8 g, 36.6 mmol, 50%) in addition to 10 as a clear oil (2.26 g,
7.03 mmol, 7%). Analytical data for 6: 1H NMR (400 MHz,
chloroform-d) δ 7.03−6.92 (m, 2H), 6.92−6.78 (m, 2H), 5.47 (d, J =
2.7 Hz, 1H), 4.75 (t, J = 9.8 Hz, 1H), 4.07 (ddd, J = 12.3, 9.9, 5.0 Hz,
1H), 3.93 (dq, J = 9.8, 6.3 Hz, 1H), 3.77 (s, 3H), 2.36 (ddd, J = 13.3,
4.9, 1.1 Hz, 1H), 2.14 (s, 3H), 1.86 (td, J = 12.9, 3.5 Hz, 1H), 1.13 (d,
J = 6.3 Hz, 3H). 13C{1H} NMR (101 MHz, chloroform-d) δ 170.1,
155.0, 150.4, 117.6, 114.7, 95.5, 76.8, 75.5, 66.7, 57.6, 55.7, 35.5, 20.9,
17.6. HRMS (ESI) m/z: [M + Na]+: calcd for C15H19N3O5Na:
344.1217; found 344.1233. Analytical data for 10: 1H NMR (400
MHz, chloroform-d) δ 6.98−6.93 (m, 2H), 6.84−6.79 (m, 2H), 5.29
(dd, J = 8.6, 2.3 Hz, 1H), 4.75 (dd, J = 8.8, 3.3 Hz, 1H), 4.27 (app q, J
= 3.6 Hz, 1H), 4.09 (dq, J = 8.8, 6.3 Hz, 1H), 3.77 (s, 3H), 2.23 (ddd,
J = 13.8, 4.4, 2.4 Hz, 1H), 2.15 (s, 3H), 2.15−2.05 (app m, 1H), 1.27
(d, J = 6.4 Hz, 3H). 13C{1H} NMR (101 MHz, chloroform-d) δ
170.2, 155.0, 150.9, 117.8, 114.5, 96.4, 74.0, 68.6, 57.4, 55.7, 35.1,
20.7, 18.1. HRMS (ESI) m/z: [M + H]+ calcd for C15H19N3O5:
344.12169, found 344.1223.
p-Methoxyphenyl-3-allyl-N-carbamate-2,3-dideoxy-4-O-triethylsil-
yl-α-L-rhamnopyranoside (7): Acetate 11 (11.8 g, 37.2 mmol) was
dissolved in MeOH (200 mL) and DCM (50 mL), NaOMe (400 mg,
7.40 mmol, 0.2 equiv) was added, and the reaction was stirred for 2
days. Dry ice was added to quench, and the reaction mixture was
concentrated in vacuo. Column chromatography (25:75 EtOAc/
pentane) afforded the title compound as a white solid (10.38 g, 3.72
mmol, quant.). 1H NMR (400 MHz, chloroform-d) δ 7.07−6.97 (m,
2H), 6.91−6.82 (m, 2H), 5.50 (d, J = 2.2 Hz, 1H), 3.99 (ddd, J =
12.1, 9.4, 4.9 Hz, 1H), 3.86 (dq, J = 9.4, 5.9 Hz, 1H), 3.81 (s, 3H),
3.25 (t, J = 9.4 Hz, 1H), 2.40 (ddd, J = 13.1, 4.9, 1.4 Hz, 1H), 2.24 (s,
1H), 1.89 (ddd, J = 13.2, 12.2, 3.5 Hz, 1H), 1.29 (d, J = 6.2 Hz, 3H).
13C{1H} NMR (101 MHz, chloroform-d) δ 154.8, 150.4, 117.6,
114.6, 95.6, 76.0, 68.3, 60.3, 55.7, 35.2, 17.8. HRMS (ESI) m/z: [M +
H]+ calcd for C13H18N3O4: 280.1297; found 280.1292.
The alcohol (370 mg, 1.32 mmol) was dissolved in dimethylfor-
mamide (DMF) (2.23 mL) and pyridine (320 μL, 3.96 mmol, 3
equiv) and cooled to 0 °C. TESOTf (0.51 mL, 2.38 mmol, 1.8 equiv)
was added, and the reaction mixture was stirred for 1.5 h at the same
temperature. Et2O (80 mL) was added, and the reaction mixture was
washed with H2O five times, dried over MgSO4, and concentrated in
vacuo. Column chromatography (5:95 EtOAc/pentane) afforded the
azide as a colorless oil (494 mg, 1.26 mmol, 95%). 1H NMR (400
MHz, chloroform-d) δ 7.04−6.98 (m, 2H), 6.89−6.82 (m, 2H), 5.47
(d, J = 2.3 Hz, 1H), 3.89 (ddd, J = 12.2, 9.2, 4.9 Hz, 1H), 3.85−3.81
(m, 1H), 3.80 (s, 3H), 3.19 (t, J = 9.2 Hz, 1H), 2.41 (ddd, J = 13.3,
4.9, 1.4 Hz, 1H), 1.88 (ddd, J = 13.2, 12.2, 3.5 Hz, 1H), 1.24 (d, J =
6.3 Hz, 3H), 1.03 (t, J = 7.9 Hz, 9H), 0.73 (qd, J = 7.9, 3.5 Hz, 6H).
13C{1H} NMR (101 MHz, chloroform-d) δ 154.8, 150.5, 117.6,
114.6, 95.5, 76.4, 69.2, 61.4, 55.6, 35.7, 18.2, 6.9, 5.2. HRMS (ESI)
m/z: [M + Na]+ calcd for C19H31N3O4SiNa: 416.1976; found
416.2671.
To a solution of the azide (1.57 g, 4.00 mmol) in THF/H2O (40
mL, 10:1 v/v) was added PPh3 (3.15 g, 20.0 mmol, 5 equiv), and the
reaction mixture was stirred for 2 days at 50 °C. Solvent was removed
in vacuo, and the residue was coevaporated with toluene twice. The
crude amine was dissolved in DCM (30 mL) and pyridine (1.0 mL,
12.9 mmol, 3.2 equiv). Allyl chloroformate (0.64 mL, 24.0 mmol, 6
equiv) was added at −20 °C, and the resulting mixture was stirred for
2 h at that temperature. It was then poured into H2O and extracted
with DCM thrice, combined organics were dried over MgSO4, and the
solvent was removed in vacuo. Purification by column chromatog-
raphy (0:100−5:95 EtOAc/pentane) afforded the title compound as a
colorless oil (1.85 g, 4.00 mmol, quant.). 1H NMR (400 MHz,
chloroform-d) δ 7.08−6.93 (m, 2H), 6.89−6.76 (m, 2H), 5.94 (ddt, J
= 16.5, 11.0, 5.7 Hz, 1H), 5.41 (d, J = 2.3 Hz, 1H), 5.33 (d, J = 16.5
Hz, 1H), 5.23 (dd, J = 10.4, 1.4 Hz, 1H), 4.59 (d, J = 5.7 Hz, 3H),
4.08 (dtd, J = 12.1, 9.2, 4.6 Hz, 1H), 3.83 (dq, J = 9.0, 6.3 Hz, 1H),
3.77 (s, 3H), 3.28 (t, J = 9.1 Hz, 1H), 2.32 (ddd, J = 13.3, 4.7, 1.5 Hz,
1H), 1.88 (t, J = 12.8 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 0.96 (t, J =
7.9 Hz, 9H), 0.62 (q, J = 7.7 Hz, 6H). 13C{1H} NMR (101 MHz,
chloroform-d) δ 169.7, 154.7, 150.9, 133.0, 118.0, 117.7, 114.6, 95.8,
76.6, 69.7, 65.7, 55.8, 51.0, 36.7, 18.6, 7.1, 5.5. HRMS (ESI) m/z: [M
+ Na]+ calcd for C22H24NO5Na: 474.2282; found 474.2289.
o-Cyclopropylethynylbenzoyl-3-N-allyloxycarbonyl-2,3-dideoxy-4-
O-triethylsilyl-β-L-rhamnopyranoside (9): Glycoside 7 (903 mg, 2.00
mmol) was hydrolyzed according to general procedure A. Column
chromatography (30:70−50:50 EtOAc/pentane) afforded hemiacetal.
The hemiacetal was esterified according to general procedure B.
Column chromatography (0:100−15:85 Et2O/pentane) afforded the
title compound as an off-white solid (498 mg, 0.97 mmol, 49%). 1H
NMR (400 MHz, chloroform-d) δ 7.91 (dd, J = 8.0, 1.4 Hz, 1H),
7.53−7.43 (m, 1H), 7.40 (dd, J = 7.7, 1.4 Hz, 1H), 7.33−7.23 (m,
1H), 6.00 (dd, J = 9.6, 2.3 Hz, 1H), 5.93 (ddt, J = 16.5, 10.9, 5.7 Hz,
1H), 5.39−5.26 (m, 1H), 5.23 (d, J = 10.4 Hz, 1H), 4.73 (d, J = 8.8
Hz, 1H), 4.58 (d, J = 5.8 Hz, 2H), 3.76 (dtd, J = 12.1, 9.1, 4.7 Hz,
1H), 3.55 (dq, J = 8.6, 6.2 Hz, 1H), 3.33−3.22 (m, 1H), 2.40 (ddd, J
= 12.7, 4.8, 2.4 Hz, 1H), 1.85 (q, J = 11.6 Hz, 1H), 1.51 (tt, J = 8.2,
6.1 Hz, 1H), 1.34 (d, J = 6.2 Hz, 3H), 0.96 (t, J = 7.9 Hz, 9H), 0.93−
0.84 (m, 4H), 0.63 (q, J = 8.0 Hz, 6H). 13C{1H} NMR (101 MHz,
chloroform-d) δ 164.2, 155.5, 134.3, 134.1, 132.8, 132.1, 131.5, 131.1,
130.9, 127.4, 127.0, 125.2, 118.0, 99.8, 92.6, 75.7, 75.0, 74.5, 65.8,
53.3, 36.6, 18.6, 9.1, 8.9, 7.0, 5.4, 0.8. HRMS (ESI) m/z: [M + Na]+
calcd for C28H39NO6SiNa: 536.2444; found 536.2437.
7-[3-N-Allyloxycarbonyl-2,3-dideoxy-4-O-triethylsilyl-α-L-rhamno-
pyranoside]-14-O-tert-butyldimethylsilyldoxorubicinone (19): Ac-
cording to general procedure C, glycosyl donor 17 (411 mg, 0.800
mmol) was coupled to 14-O-tert-butyldimethylsilyl-doxorubicinone
18 (555 mg, 1.05 mmol, 1.3 equiv). Column chromatography (3:97−
10:90 EtOAc/toluene) afforded the title compound as a red solid
(545 mg, 0.64 mmol, 80%, 8:1 α/β). Spectral data for the α-anomer:
1H NMR (400 MHz, chloroform-d) δ 13.96 (d, J = 2.6 Hz, 1H),
13.26 (d, J = 2.8 Hz, 1H), 8.03 (d, J = 6.4 Hz, 1H), 7.78 (td, J = 8.2,
2.2 Hz, 1H), 7.39 (d, J = 7.7 Hz, 1H), 5.99−5.78 (m, 1H), 5.47−5.40
(m, 1H), 5.27 (d, J = 15.3 Hz, 2H), 5.18 (d, J = 10.6 Hz, 1H), 5.03−
4.86 (m, 2H), 4.57 (s, 1H), 4.08 (d, J = 2.1 Hz, 3H), 3.82 (d, J = 7.5
Hz, 1H), 3.63 (d, J = 9.6 Hz, 1H), 3.29 (s, 1H), 3.21 (d, J = 18.7 Hz,
1H), 2.98 (dd, J = 19.3, 2.8 Hz, 1H), 2.34 (d, J = 14.8 Hz, 1H), 2.16
(d, J = 15.1 Hz, 1H), 2.10 (d, J = 13.4 Hz, 1H), 1.81 (s, 1H), 1.30
(dd, J = 6.3, 2.1 Hz, 3H), 1.04−0.91 (m, 19H), 0.62 (qd, J = 7.9, 2.1
Hz, 6H), 0.14 (d, J = 2.1 Hz, 6H). 13C{1H} NMR (101 MHz,
chloroform-d) δ 211.9, 187.3, 186.9, 161.2, 156.6, 156.1, 135.8, 134.5,
134.0, 121.1, 111.6, 111.5, 90.0, 77.6, 77.3, 77.2, 76.9, 66.9, 36.0, 34.2,
18.8, 5.5. HRMS (ESI) m/z: [M + Na]+ calcd for C43H61NO13Si2Na:
878.3574; found 878.3599.
N,N-Dimethyl-4′-epi-doxorubicin (2b): To a solution of 19 (135
mg, 0.158 mmol) and 1,3-dimethylbarbituric acid (74 mg, 0.47 mmol,
3 equiv) in DCM (15 mL) was portion-wise added Pd(PPh3)4 (18.5
mg, 0.016 mmol, 0.1 equiv). The reaction mixture was stirred
overnight, and the solvent was removed in vacuo. The residue was
submitted to column chromatography (3:97−15:85 acetone/toluene)
to afford the free amine as a red solid. 1H NMR (400 MHz,
chloroform-d) δ 13.93 (s, 1H), 8.00 (dd, J = 7.8, 1.1 Hz, 1H), 7.76
(dd, J = 8.4, 7.8 Hz, 1H), 7.39 (dd, J = 8.6, 1.1 Hz, 1H), 5.43 (d, J =
3.8 Hz, 1H), 5.25 (dd, J = 4.1, 2.1 Hz, 1H), 5.03−4.82 (m, 2H), 4.73
(s, 1H), 4.08 (s, 3H), 3.73 (dq, J = 8.9, 6.2 Hz, 1H), 3.16 (dd, J =
19.0, 2.0 Hz, 1H), 3.06 (t, J = 8.9 Hz, 1H), 2.92 (d, J = 18.9 Hz, 1H),
2.87 (dt, J = 8.7, 4.1 Hz, 1H), 2.34 (dt, J = 14.7, 2.2 Hz, 1H), 2.18−
2.05 (m, 1H), 1.95 (dd, J = 13.4, 4.4 Hz, 1H), 1.62−1.54 (m, 1H),
1.29 (d, J = 6.3 Hz, 3H), 1.05−0.93 (m, 18H), 0.69 (q, J = 8.1 Hz,
6H), 0.14 (s, 6H). 13C{1H} NMR (101 MHz, chloroform-d) δ 211.7,
187.1, 186.7, 161.1, 156.5, 155.9, 135.8, 135.6, 134.4, 134.1, 120.9,
119.9, 118.5, 111.5, 111.3, 100.7, 80.4, 70.0, 69.6, 66.8, 56.8, 50.3,
37.9, 35.8, 34.0, 26.0, 18.7, 18.4, 7.1, 5.7, −5.2. HRMS (ESI) m/z: [M
+ H]+ calcd for C39H59NO11Si2: 772.3543; found 772.3568.
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To a solution of the amine in EtOH (10 mL) were added
formaldehyde solution (aqueous 37% w/v, 0.31 mL, 3.9 mmol, 30
equiv) and sodium trisacetoxyborohydride (52 mg, 0.24 mmol, 1.95
equiv). After stirring for 1.5 h, the reaction mixture was partitioned
between DCM and sat. aq. NaHCO3 and extracted thrice with DCM.
Combined organics were dried over Na2SO4 and concentrated in
vacuo. Purification by column chromatography (1:200−10:90
acetone/toluene) afforded the title compound as a red solid (77
mg, 96 μmol, 61% over two steps). 1H NMR (400 MHz, chloroform-
d) δ 13.97 (s, 1H), 13.26 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (t, J =
7.9 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 5.50 (d, J = 3.9 Hz, 1H), 5.25
(d, J = 3.1 Hz, 1H), 5.06−4.85 (m, 2H), 4.79 (s, 1H), 4.09 (s, 3H),
3.82−3.68 (m, 1H), 3.32−3.12 (m, 2H), 3.00 (d, J = 18.8 Hz, 1H),
2.51 (d, J = 13.4 Hz, 1H), 2.37 (d, J = 14.7 Hz, 1H), 2.14 (d, J = 4.6
Hz, 6H), 1.89−1.79 (m, 1H), 1.60 (td, J = 12.9, 4.2 Hz, 1H), 1.31 (d,
J = 6.1 Hz, 3H), 1.02−0.91 (m, 18H), 0.60 (qd, J = 7.6, 3.4 Hz, 6H),
0.14 (s, 6H). 13C{1H} NMR (101 MHz, chloroform-d) δ 211.8,
187.3, 186.8, 161.1, 156.6, 156.1, 135.8, 135.7, 134.6, 134.3, 121.1,
119.9, 118.5, 111.5, 111.4, 101.5, 73.6, 71.2, 69.8, 66.8, 61.8, 56.8,
40.7, 35.8, 34.0, 26.2, 26.0, 18.8, 18.7, 7.2, 5.6, −5.3. HRMS (ESI) m/
z: [M + H]+ calcd for C41H62NO11Si2: 800.3856; found 800.3888.
According to general procedure D, the above dimethylamine (33
mg, 41 μmol) was desilylated. Column chromatography on neutral
silica (0:100−20:80 MeOH/DCM) afforded the title compound as a
red solid (24 mg, 41 μmol, quant.). 1H NMR (500 MHz, chloroform-
d) δ 13.95 (s, 1H), 13.16 (s, 1H), 7.99 (dd, J = 7.7, 1.1 Hz, 1H), 7.77
(dd, J = 8.5, 7.6 Hz, 1H), 7.39 (dd, J = 8.6, 1.1 Hz, 1H), 5.56 (d, J =
3.9 Hz, 1H), 5.29 (s, 1H), 5.26 (dd, J = 4.2, 2.1 Hz, 1H), 4.88−4.71
(m, 2H), 4.08 (s, 3H), 3.80 (dq, J = 9.0, 6.2 Hz, 1H), 3.23−3.12 (m,
2H), 2.90 (d, J = 18.7 Hz, 1H), 2.63 (ddd, J = 13.3, 9.9, 3.8 Hz, 1H),
2.38 (dt, J = 14.8, 2.2 Hz, 1H), 2.20 (s, 6H), 2.17 (dd, J = 14.7, 4.1
Hz, 1H), 1.84 (ddd, J = 13.2, 4.0, 1.3 Hz, 1H), 1.63 (td, J = 13.0, 4.2
Hz, 1H), 1.35 (d, J = 6.2 Hz, 3H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 214.2, 187.2, 186.7, 161.1, 156.4, 155.8, 135.9, 135.5,
133.9, 133.9, 120.9, 120.0, 118.6, 111.6, 111.4, 101.5, 76.8, 71.5, 70.8,
69.8, 65.7, 61.9, 56.8, 40.0, 35.7, 34.0, 25.9, 18.4. HRMS (ESI) m/z:
[M + H]+ calcd for C29H35NO11: 572.2126; found 572.2134.
p-Methoxyphenyl-3-epi-azido-α-L-daunosamine (14): Anomeric
acetate 13 (7.92 g, 24.8 mmol) and p-methoxyphenol (4.62 g, 37.2
mmol, 1.5 equiv) were coevaporated with toluene. DCM (880 mL)
and activated molecular sieves (4 Å) were added, and the reaction was
stirred for 30 min at room temperature. BF3·OEt2 (7.65 mL, 62 mmol,
2.5 equiv) was added at −60 °C, and the reaction mixture was allowed
to gradually warm up from −60 to −40 °C over 2.5 h. The reaction
mixture was poured into a saturated aqueous solution of NaHCO3,
extracted with DCM, washed twice with NaOH, dried over MgSO4,
and concentrated in vacuo. The residue was dissolved in MeOH (42
mL), to which NaOMe (284 mg, 5.0 mmol, 0.2 equiv) was added
after which the reaction mixture was stirred for 4 days. Dry ice was
added, and the reaction mixture was concentrated in vacuo. Column
chromatography (8:92−40:60 EtOAc/pentane) afforded the title
compound as a white solid (3.98 g, 15.7 mmol, 70%). 1H NMR (400
MHz, chloroform-d) δ 7.13−6.94 (m, 2H), 6.94−6.73 (m, 2H), 5.46
(dd, J = 4.3, 1.4 Hz, 1H), 4.43 (qd, J = 6.7, 1.4 Hz, 1H), 4.00 (dt, J =
4.2, 3.1 Hz, 1H), 3.80 (s, 3H), 3.43 (s, 1H), 2.35 (dt, J = 15.3, 4.4 Hz,
1H), 2.26−2.05 (m, 2H), 1.22 (d, J = 6.7 Hz, 3H). 13C{1H} NMR
(101 MHz, chloroform-d) δ 154.8, 151.0, 117.8, 114.6, 95.3, 69.0,
62.7, 57.1, 55.7, 29.7, 27.0, 16.3. HRMS (ESI) m/z: [M + H]+ calcd
for C13H18N3O4: 280.1297; found 280.1292.
p-Methoxyphenyl-3-epi-N-allyloxycarbonyl-4-O-triethylsilyl-α-L-
daunosamine (15): To a solution of 14 (1.22 g, 4.38 mmol) in DMF
(7.4 mL) and pyridine (1.06 mL, 13.1 mmol, 3 equiv) was added
TESOTf (1.8 mL, 7.88 mmol, 1.8 equiv) at 0 °C, and the reaction
mixture was stirred for 1 h. It was subsequently poured into EtOAc,
washed with H2O, dried over MgSO4, and concentrated in vacuo. The
residue was dissolved in THF/H2O (165 mL, 10:1 v/v), PPh3 (2.30 g,
8.76 mmol, 2 equiv) was added, and the reaction mixture was stirred
for 3 days after which it was concentrated in vacuo. The amine thus
obtained was coevaporated with toluene thrice and dissolved in DCM
(31.4 mL) and pyridine (1.1 mL, 14 mmol, 3.2 equiv). Allyl
chloroformate (0.70 mL, 6.6 mmol, 1.5 equiv) was added at −25 °C,
and the reaction mixture was stirred at that temperature for 1 h. The
mixture was left to warm to room temperature and diluted with DCM,
washed with H2O, dried over MgSO4, and concentrated in vacuo.
Purification by column chromatography (2:98:1−40:60:1 Et2O/
pentane/Et3N) afforded the title compound as a colorless oil (1.98
g, 4.38 mmol, quant. over three steps). 1H NMR (400 MHz,
chloroform-d) δ 7.07−6.98 (m, 2H), 6.91−6.77 (m, 2H), 6.29 (d, J =
7.8 Hz, 1H), 5.96 (ddt, J = 17.2, 10.3, 5.6 Hz, 1H), 5.48 (d, J = 3.7
Hz, 1H), 5.41−5.16 (m, 2H), 4.72−4.50 (m, 2H), 4.26−4.13 (m,
1H), 3.90 (ddt, J = 7.9, 5.4, 2.7 Hz, 1H), 3.78 (s, 3H), 3.53 (d, J = 3.4
Hz, 1H), 2.52−2.32 (m, 1H), 1.79 (ddt, J = 14.4, 2.4, 1.2 Hz, 1H),
1.16 (d, J = 6.5 Hz, 3H), 1.06−0.95 (m, 9H), 0.80−0.64 (m, 6H).
13C{1H} NMR (101 MHz, chloroform-d) δ 155.7, 155.1, 150.7,
133.1, 118.0, 117.9, 114.7, 97.6, 69.4, 65.7, 63.4, 55.8, 49.1, 27.9, 17.2,
7.0, 4.9. HRMS (ESI) m/z: [M + Na]+ calcd for C19H31N3O4SiNa:
474.2282; found 474.2289.
o-Cyclopropylethynylbenzoyl-3-epi-N-allyloxycarbonyl-4-O-trie-
thylsilyl-L-daunosamine (16): Glycoside 15 (990 mg, 2.19 mmol)
was hydrolyzed according to general procedure A. The hemiacetal
thus obtained was esterified according to general procedure B.
Column chromatography (0:100−15:85 Et2O/pentane) afforded the
title compound as a pale-yellow oil (879 mg, 1.71 mmol, 79%, 3:1 α/
β). Spectral data for the α-anomer: 1H NMR (400 MHz, chloroform-
d): δ 7.96 (dd, J = 8.0, 1.4 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H, NH), 7.47
(dt, J = 7.5, 1.9 Hz, 1H), 7.44−7.38 (m, 1H), 7.34−7.27 (m, 1H),
6.09 (dd, J = 9.2, 2.5 Hz, 1H), 5.93 (ddd, J = 16.2, 10.8, 5.4 Hz, 1H),
5.37−5.22 (m, 2H), 4.59 (s, 2H), 4.00 (dt, J = 6.5, 2.9 Hz, 2H), 3.57
(s, 1H), 2.42−2.34 (m, 1H), 1.88−1.78 (m, 1H), 1.31−1.27 (m, 3H),
1.27−1.23 (m, 1H), 0.98 (t, J = 7.9 Hz, 9H), 0.91−0.88 (m, 4H),
0.73−0.65 (m, 8H). 13C{1H} NMR (100 MHz, chloroform-d): δ
164.7, 155.6, 134.9, 134.3, 132.1, 130.8, 127.2, 99.9, 91.8, 74.6, 71.5,
69.3, 65.9, 50.7, 30.6, 17.0, 9.0, 7.1, 4.85, 0.8. HRMS (ESI) m/z: [M +
Na]+ calcd for C28H39NO6SiNa: 536.24389; found 536.24362.
7-[3-epi-N-Allyloxycarbonyl-4-O-triethylsilyl-α-L-daunosamino]-
14-O-tert-butyldimethylsilyldoxorubicinone (21): According to
general procedure C, glycosyl donor 16 (384 mg, 0.769 mmol) was
coupled to 14-O-tert-butyldimethylsilyl-doxorubicinone 18 (593 mg,
1.12 mmol, 1.5 equiv). Column chromatography (2:98−10:90
acetone/toluene) and size-exclusion chromatography (Sephadex
LH-20, 1:1 DCM/MeOH v/v) afforded the title compound as a
red solid (368 mg, 0.43 mmol, 56%). 1H NMR (400 MHz,
chloroform-d) δ 13.95 (s, 1H), 13.24 (s, 1H), 7.99 (dd, J = 7.7, 1.0
Hz, 1H), 7.76 (t, J = 8.1 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.71 (d, J
= 7.7 Hz, 1H), 6.00−5.80 (m, 1H), 5.50 (d, J = 3.7 Hz, 1H), 5.40−
5.01 (m, 3H), 4.74 (s, 2H), 4.51 (dt, J = 5.5, 1.5 Hz, 2H), 4.20−4.13
(m, 1H), 4.11 (s, 1H), 4.08 (s, 3H), 3.81−3.71 (m, 1H), 3.49 (d, J =
3.6 Hz, 1H), 3.19 (d, J = 18.8 Hz, 1H), 3.02 (d, J = 18.8 Hz, 1H),
2.39−2.09 (m, 3H), 1.21 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 24.0 Hz,
19H), 0.70 (q, J = 7.7 Hz, 6H), 0.15 (d, J = 1.3 Hz, 6H). 13C{1H}
NMR (101 MHz, chloroform-d) δ 210.9, 187.1, 186.7, 161.1, 156.8,
155.8, 135.8, 135.6, 135.1, 133.7, 133.3, 121.0, 119.8, 118.5, 117.3,
111.5, 111.2, 99.4, 76.1, 69.5, 67.0, 66.9, 65.3, 63.6, 56.8, 48.7, 35.2,
33.5, 27.4, 25.9, 18.5, 17.2, 7.1, 4.9, −5.3. HRMS (ESI) m/z: [M +
Na]+ calcd for C43H61NO13Si2Na: 878.35740; found 878.35817.
3′-epi-Doxorubicin (3a): To a solution of 21 (46 mg, 54 μmol) in
DCM (5 mL) were added 1,3-dimethylbarbituric acid (25 mg, 0.16
mmol, 3 equiv) and Pd(PPh3)4 (27 mg, 5.4 μmol, 0.1 equiv). The
reaction mixture was stirred for 1.5 h, after which solvent was
removed in vacuo. The residue was submitted to column
chromatography (0:100−10:90 acetone/toluene) to afford the
crude amine. The crude amine was desilylated according to general
procedure D. Column chromatography on neutral silica (0:100−
50:50 MeOH/DCM) afforded the title compound as a red solid (18
mg, 33 μmol, 61% over two steps). 1H NMR (500 MHz, chloroform-
d) δ 13.93 (s, 1H), 8.04 (dd, J = 7.7, 1.1 Hz, 1H), 7.79 (dd, J = 8.5,
7.7 Hz, 1H), 7.39 (dd, J = 8.6, 1.1 Hz, 1H), 5.46−5.37 (m, 1H), 5.25
(dd, J = 3.7, 2.4 Hz, 1H), 4.79 (s, 2H), 4.59−4.42 (m, 1H), 4.09 (s,
3H), 3.79−3.66 (m, 1H), 3.08 (d, J = 18.9 Hz, 1H), 2.39 (dt, J = 14.7,
2.2 Hz, 1H), 2.21−2.04 (m, 2H), 1.94−1.80 (m, 2H), 1.46 (d, J =
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12.1 Hz, 2H), 1.29 (d, J = 6.7 Hz, 3H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 214.8, 187.2, 186.8, 161.2, 156.3, 156.0, 135.8, 135.7,
134.6, 134.0, 121.1, 119.9, 118.5, 111.6, 111.3, 100.0, 76.4, 72.0, 68.3,
65.7, 62.9, 48.7, 35.5, 34.1, 31.2, 16.4. HRMS (ESI) m/z: [M + H+]
calcd for C27H30NO11: 544.1813; found 544.1812.
N,N-Dimethyl-3′-epidoxorubicin (3b): To a solution of 21 (34 mg,
40 μmol) in DCM (4.0 mL) was added 1,3-dimethylbarbituric acid
(19 mg, 119 μmol, 3 equiv). Pd(PPh3)4 (5 mg, 4 μmol, 0.1 equiv) was
added, and the reaction mixture was stirred for 1 h, after which it was
concentrated in vacuo. The residue was submitted to column
chromatography (0:100−15:85 acetone/toluene) to give the crude
amine. To a solution of this amine in EtOH (2.5 mL) were added
formaldehyde (aqueous 37% w/v solution, 0.1 mL, mmol, 30 equiv)
and sodium trisacetoxyborohydride (14 mg, 66 μmol, 1.65 equiv).
The reaction mixture was stirred for 2 h and partitioned between
DCM and sat. aq. NaHCO3. The aqueous layer was extracted with
DCM, combined organics were dried over Na2SO4, and concentrated
in vacuo. Purification by column chromatography (0:100−10:90
acetone in toluene) afforded the dimethylamine as a red solid (23 mg,
29 μmol, 72%). 1H NMR (400 MHz, chloroform-d) δ 13.85 (s, 1H),
13.31 (s, 1H), 8.02 (dd, J = 7.7, 1.1 Hz, 1H), 7.76 (dd, J = 8.5, 7.7 Hz,
1H), 7.38 (dd, J = 8.6, 1.2 Hz, 1H), 5.34 (d, J = 3.7 Hz, 1H), 5.18
(dd, J = 3.6, 2.3 Hz, 1H), 5.00−4.90 (m, 2H), 4.24 (h, J = 5.7 Hz,
1H), 4.08 (s, 3H), 3.77−3.71 (m, 1H), 3.44−3.26 (m, 1H), 3.22−
2.98 (m, 2H), 2.39−2.26 (m, 1H), 2.15 (s, 6H), 2.12−1.98 (m, 3H),
1.82−1.70 (m, 1H), 1.21 (d, J = 6.5 Hz, 3H), 1.03−0.93 (m, 19H),
0.71−0.56 (m, 6H), 0.14 (d, J = 3.7 Hz, 6H). 13C{1H} NMR (101
MHz, chloroform-d) δ 213.0, 187.2, 186.8, 161.1, 156.5, 156.3, 135.8,
135.7, 135.4, 134.7, 121.2, 119.8, 118.4, 111.3, 111.1, 99.9, 76.8, 68.9,
67.7, 66.8, 64.7, 64.0, 56.8, 44.0, 35.7, 34.0, 26.0, 25.6, 18.8, 17.5, 7.1,
5.1, −5.1, −5.3. HRMS (ESI) m/z: [M + H]+ calcd for
C41H62NO11Si2: 800.3856; found 800.3880.
According to general procedure D, the above dimethylamine (19
mg, 24 μmol) was desilylated. Column chromatography on neutral
silica (0:100−20:80 MeOH:DCM) afforded the title compound as a
red solid (9.0 mg, 16 μmol, 66%). 1H NMR (500 MHz, chloroform-
d) δ 13.95 (s, 1H), 13.27 (s, 1H), 8.04 (dd, J = 7.7, 1.1 Hz, 1H), 7.80
(dd, J = 8.5, 7.7 Hz, 1H), 7.41 (dd, J = 8.6, 1.1 Hz, 1H), 5.36 (dd, J =
5.5, 3.9 Hz, 1H), 5.28 (dd, J = 3.7, 2.3 Hz, 1H), 4.80 (s, 2H), 4.38
(qd, J = 6.8, 3.4 Hz, 1H), 4.10 (s, 3H), 3.74 (dd, J = 6.6, 3.4 Hz, 1H),
3.23 (dd, J = 18.9, 2.0 Hz, 1H), 3.04 (d, J = 18.8 Hz, 1H), 2.52−2.41
(m, 2H), 2.23 (s, 6H), 2.11 (dd, J = 14.7, 3.8 Hz, 1H), 1.98 (dt, J =
14.0, 3.8 Hz, 1H), 1.60 (ddd, J = 13.7, 8.0, 5.5 Hz, 1H), 1.32 (d, J =
6.8 Hz, 3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 215.0, 187.2,
186.8, 161.1, 156.3, 156.0, 135.7, 134.3, 134.3, 121.0, 119.9, 111.5,
111.3, 99.7, 77.4, 77.1, 76.9, 76.4, 76.4, 68.5, 68.2, 66.9, 65.7, 62.6,
56.8, 35.6, 34.0, 26.4, 26.4, 15.1. HRMS (ESI) m/z: [M + H]+ calcd
for C29H35NO11: for 572.2126; found 572.2131.
p-Methoxyphenyl-3-N-allyloxycarbonyl-4-O-triethylsilyl-2,3,6-tri-
deoxy-3-azido-β-L-ribohexapyranoside (11): To a solution of 10
(2.26 g, 7.03 mmol) in MeOH (120 mL) was added sodium
methoxide (76 mg, 1.41 mmol, 0.2 equiv). After stirring for 2 days,
the reaction mixture was quenched by addition of dry ice. Solvent was
removed in vacuo and coevaporated thrice with toluene. The residue
was purified by column chromatography (10:90−50:50
Et2O:pentane) to afford the alcohol as a pale-yellow oil (1.96 g,
7.03 mmol, quant.). 1H NMR (400 MHz, chloroform-d) δ 7.03−6.89
(m, 2H), 6.90−6.76 (m, 2H), 5.27 (dd, J = 8.9, 2.3 Hz, 1H), 4.11 (q, J
= 3.7 Hz, 1H), 3.80 (dt, J = 8.7, 6.3 Hz, 1H), 3.76 (s, 3H), 3.48 (td, J
= 8.3, 3.6 Hz, 1H), 2.28 (ddd, J = 13.8, 4.2, 2.3 Hz, 1H), 2.13−1.99
(m, 1H), 1.32 (d, J = 6.3 Hz, 3H). 13C{1H} NMR (101 MHz,
chloroform-d) δ 155.0, 151.1, 117.7, 114.6, 96.3, 72.4, 70.8, 60.7, 55.7,
35.1, 18.2. HRMS (ESI) m/z: [M + Na]+ calcd for C13H17N3O4Na:
302.1111; found 302.1118.
To a solution of the above alcohol (1.12 g, 4.00 mmol) in pyridine
(20 mL) was added TESOTf (1.29 mL, 1.59 g, 6.00 mmol, 1.5 equiv).
The reaction mixture was stirred for 30 min and then diluted with
DCM, washed twice with 1 M HCl, sat. aq. NaHCO3 and brine, dried
over MgSO4, and concentrated in vacuo. Purification by column
chromatography (0:100−7:93 Et2O:pentane) afforded the title
compound as a colorless oil (1.57 g, 4.0 mmol, quant.). 1H NMR
(400 MHz, chloroform-d) δ 6.97−6.90 (m, 2H), 6.86−6.75 (m, 2H),
5.25 (dd, J = 9.0, 2.3 Hz, 1H), 3.98 (q, J = 3.5 Hz, 1H), 3.96−3.87
(m, 1H), 3.77 (s, 3H), 3.62 (dd, J = 8.7, 3.3 Hz, 1H), 2.17 (ddd, J =
13.6, 4.0, 2.3 Hz, 1H), 1.96 (ddd, J = 13.6, 9.0, 3.4 Hz, 1H), 1.28 (d, J
= 6.3 Hz, 3H), 1.00 (t, J = 7.9 Hz, 9H), 0.68 (qd, J = 8.3, 7.9, 1.7 Hz,
6H). 13C{1H} NMR (101 MHz, chloroform-d) δ 155.0, 151.2, 117.8,
114.6, 96.5, 74.8, 70.8, 60.8, 55.8, 35.8, 18.5, 7.0, 5.0. HRMS (ESI)
m/z: [M + Na]+ calcd for C19H31N3O4SiNa: 416.1976; found
416.1983.
To a solution of the above azide (1.57 g, 4.00 mmol) in THF/H2O
(40 mL, 10:1 v/v) was added PPh3 (2.10 g, 8.00 mmol, 2 equiv), and
the reaction mixture was stirred overnight at 50 °C. Solvent was
removed in vacuo, and the residue was coevaporated with toluene
twice. The crude amine was dissolved in DCM (30 mL), and pyridine
(1 mL) to which allyl chloroformate (0.64 mL, 24 mmol, 6 equiv) was
added at −20 °C. This mixture was stirred for 1 h at this temperature.
It was then poured into H2O and extracted with DCM thrice, organic
layers dried over MgSO4, and concentrated in vacuo. Purification by
column chromatography (1:200 Et3N:pentane) afforded the title
compound as a colorless oil (1.81 g, 4.00 mmol, quant.). 1H NMR
(400 MHz, chloroform-d) δ 7.03−6.91 (m, 2H), 6.87−6.70 (m, 2H),
5.93 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 5.43−5.25 (m, 2H), 5.22 (dq, J
= 10.4, 1.4 Hz, 1H), 5.04 (s, 1H), 4.65−4.45 (m, 2H), 4.11 (q, J =
4.9, 4.2 Hz, 1H), 3.77 (s, 4H), 3.63 (dd, J = 6.7, 4.0 Hz, 1H), 2.51
(dd, J = 14.0, 6.3 Hz, 1H), 1.90 (ddd, J = 13.5, 7.0, 3.7 Hz, 1H), 1.28
(d, J = 6.5 Hz, 3H), 0.96 (t, J = 7.9 Hz, 9H), 0.63 (q, J = 7.7 Hz, 6H).
13C{1H} NMR (101 MHz, chloroform-d) δ 156.3, 154.8, 151.4,
132.9, 117.9, 117.6, 114.6, 97.0, 72.6, 71.9, 65.7, 55.8, 48.4, 19.2, 6.9,
5.0. HRMS (ESI) m/z: [M + Na]+ calcd for C23H37NO6SiNa:
474.2282; found 474.2290.
o-Cyclopropylethynylbenzoyl-3-N-allyloxycarbonyl-4-O-triethylsil-
yl-2,3,6-trideoxy-L-ribohexapyranoside (12): Glycoside 11 (1.71 g,
3.80 mmol) was hydrolyzed according to general procedure A.
Column chromatography (90:10 EtOAc/pentane) afforded the
hemiacetal. The resulting hemiacetal was esterified according to
general procedure B. Column chromatography (0:100−10:90
Et2O:pentane) afforded the title compound as a pale-yellow oil
(1.11 g, 2.20 mmol, 57% over two steps, 1:3 α/β). Spectral data for
the β-anomer: 1H NMR (500 MHz, chloroform-d) δ 7.91 (dd, J = 8.0,
1.3 Hz, 1H), 7.47 (dd, J = 7.9, 1.3 Hz, 1H), 7.41 (tt, J = 7.7, 1.2 Hz,
1H), 7.33−7.27 (m, 1H), 6.27 (dd, J = 6.6, 2.8 Hz, 1H), 5.93 (dddd, J
= 18.0, 10.5, 6.1, 5.2 Hz, 1H), 5.32 (dq, J = 17.2, 1.3 Hz, 1H), 5.23
(dq, J = 10.4, 1.3 Hz, 1H), 5.06 (s, 1H), 4.59 (q, J = 6.8, 6.2 Hz, 2H),
4.15 (tq, J = 6.6, 3.7 Hz, 1H), 3.91 (p, J = 6.5 Hz, 1H), 3.67 (dd, J =
6.1, 3.9 Hz, 1H), 2.55−2.39 (m, 1H), 1.93 (ddd, J = 13.5, 6.6, 3.8 Hz,
1H), 1.53 (tt, J = 8.1, 5.6 Hz, 1H), 1.32 (d, J = 6.6 Hz, 3H), 0.97 (dd,
J = 8.3, 7.5 Hz, 9H), 0.92−0.83 (m, 4H), 0.63 (q, J = 7.8 Hz, 6H).
13C{1H} NMR (126 MHz, chloroform-d) δ 164.6, 156.2, 134.4,
132.9, 131.9, 131.2, 130.6, 127.1, 125.2, 117.9, 99.8, 92.1, 74.6, 73.6,
71.5, 65.8, 47.6, 32.2, 19.3, 9.0, 6.9, 5.0, 0.8. HRMS (ESI) m/z: [M +
Na]+ calcd for C28H39NO6SiNa: 536.2434; found 536.2450.
7-[3-Allyl-N-allyloxycarbonyl-4-O-triethylsilyl-2,3,6-trideoxy-L-ri-
bohexapyranoside]-14-O-tert-butyldimethylsilyldoxorubicinone
(20): According to general procedure C, glycosyl donor 12 (128 mg,
0.240 mmol) was coupled to 14-O-tert-butyldimethylsilyldoxorubici-
none 18 (198 mg, 0.37 mmol, 1.5 equiv). Column chromatography
(0:100−5:95 EtOAc/pentane to 1:99−3:97 acetone/toluene) gave
the title compound as a red solid (103 mg, 0.120 mmol, 50%, 1.5:1 α/
β). Spectral data for the α-anomer: 1H NMR (500 MHz, chloroform-
d) δ 13.92 (s, 1H), 13.22 (s, 1H), 7.98 (dd, J = 7.7, 1.1 Hz, 1H), 7.74
(t, J = 8.1 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 5.82 (ddt, J = 17.3, 10.6,
5.4 Hz, 1H), 5.71 (d, J = 6.7 Hz, 1H), 5.40 (dd, J = 4.4, 2.3 Hz, 1H),
5.26−5.17 (m, 2H), 5.07 (dq, J = 10.5, 1.5 Hz, 1H), 4.95−4.78 (m,
2H), 4.54−4.37 (m, 3H), 4.07 (s, 3H), 3.93 (dq, J = 12.5, 6.5 Hz,
2H), 3.49 (dd, J = 8.6, 4.1 Hz, 1H), 3.17 (dd, J = 18.9, 1.8 Hz, 1H),
3.00 (d, J = 18.8 Hz, 1H), 2.34 (dt, J = 14.7, 2.1 Hz, 1H), 2.17 (dd, J
= 14.7, 4.2 Hz, 1H), 2.09 (ddd, J = 14.5, 4.5, 2.3 Hz, 1H), 1.86 (dt, J
= 14.4, 4.3 Hz, 1H), 1.29 (d, J = 6.3 Hz, 3H), 0.99−0.93 (m, 18H),
0.71−0.59 (m, 6H), 0.15 (s, 6H). 13C{1H} NMR (126 MHz,
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chloroform-d) δ 211.3, 186.9, 186.6, 161.0, 156.4, 156.3, 155.7, 135.6,
135.5, 134.5, 134.0, 133.1, 120.9, 119.7, 118.4, 116.9, 111.4, 111.2,
98.9, 72.5, 66.8, 66.4, 65.1, 56.7, 48.4, 35.6, 33.7, 33.4, 25.8, 18.5,
18.1, 6.8, 4.8, −5.5. HRMS (ESI) m/z: [M + Na+] calcd for
C43H61NO13Si2Na: 878.3574; found 878.3602.
3′-4′-Di-epi-doxorubicin Hydrochloride (4a): To a solution of 20
(45 mg, 53 μmol) in DCM (5 mL) were added 1,3-dimethylbarbituric
acid (25 mg, 0.16 mmol, 3 equiv) and Pd(PPh3)4 (6.0 mg, 5.3 μmol,
0.1 equiv). The reaction mixture was stirred overnight, and solvent
was removed in vacuo. The residue was submitted to column
chromatography (1:99−15:85 acetone/toluene) to give the crude
amine. The crude amine thus obtained was desilylated according to
general procedure D. Column chromatography on neutral silica
(0:100−50:50 MeOH/DCM), and lyophilization from aqueous 10
μM HCl (1 mL/μmol, 2 equiv) afforded the title compound as a dark
red solid (17 mg, 29 μmol, 54% over two steps). 1H NMR (500 MHz,
DMSO-d6) δ 13.98 (s, 1H), 13.22 (s, 1H), 7.92 (q, J = 4.4, 3.8 Hz,
2H), 7.80−7.55 (m, 4H), 6.29 (s, 1H), 6.18 (d, J = 4.8 Hz, 1H), 5.30
(d, J = 3.3 Hz, 1H), 5.04−4.89 (m, 2H), 4.73−4.43 (m, 2H), 3.99 (s,
3H), 3.98−3.91 (m, 1H), 3.46 (dt, J = 9.3, 4.5 Hz, 3H), 3.17 (d, J =
18.8 Hz, 1H), 3.00 (d, J = 18.8 Hz, 1H), 2.24 (d, J = 14.8 Hz, 1H),
2.11−1.81 (m, 3H), 1.28 (d, J = 6.1 Hz, 3H). 13C{1H} NMR (126
MHz, DMSO-d6) δ 214.0, 187.2, 187.1, 161.4, 156.1, 155.1, 136.9,
135.3, 135.1, 134.6, 120.5, 120.4, 119.6, 111.4, 111.3, 98.7, 75.7, 68.9,
68.6, 65.0, 64.4, 57.2, 49.7, 40.4, 35.6, 32.1, 31.7, 18.0. HRMS (ESI)
m/z: [M + H+] calcd for C27H31NO11: 544.1813; found 544.1814.
3′-4′-Di-epi-dimethyldoxorubicin (4b): To a solution of 20 (73 mg,
85 μmol) in DCM (6 mL) was added 1,3-dimethylbarbituric acid (40
mg, 0.26 mmol, 3 equiv). Pd(PPh3)4 (9.0 mg, 8.5 μmol, 0.1 equiv)
was added, and the reaction mixture was stirred overnight. After
concentrating in vacuo, the residue was submitted to silica gel column
chromatography (0:100−15:85 acetone/toluene) to give the crude
amine. To a solution of the crude amine in EtOH (4 mL) was added
formaldehyde (aqueous 37% w/v solution, 0.13 mL) and sodium
trisacetoxyborohydride (22.5 mg, 106 μmol, 1.25 equiv). The reaction
mixture was stirred for 2 h, partitioned between DCM and sat. aq.
NaHCO3, and the aqueous layer was extracted thrice with DCM.
Combined organics were dried over Na2SO4 and concentrated in
vacuo, followed by purification through column chromatography
(0:100−20:80 acetone/toluene) to give the crude dimethylamine.
This was then desilylated according to general procedure D. Column
chromatography on neutral silica (0:100−7:93 MeOH:DCM)
afforded the title compound as a red solid (17 mg, 30 μmol, 35%
over three steps). 1H NMR (500 MHz, chloroform-d) δ 13.99 (s,
1H), 13.22 (s, 1H), 8.03 (dd, J = 7.7, 1.1 Hz, 1H), 7.79 (dd, J = 8.5,
7.7 Hz, 1H), 7.40 (dd, J = 8.6, 1.1 Hz, 1H), 5.38 (dd, J = 8.8, 4.8 Hz,
1H), 5.30 (dd, J = 4.1, 2.1 Hz, 1H), 4.85−4.71 (m, 2H), 4.09 (s, 3H),
4.02 (dd, J = 6.8, 5.3 Hz, 1H), 3.64−3.53 (m, 1H), 3.24 (dd, J = 18.8,
2.1 Hz, 1H), 2.95 (d, J = 18.7 Hz, 1H), 2.55 (dt, J = 14.6, 2.2 Hz,
1H), 2.37−2.31 (m, 6H), 2.31 (s, 6H), 2.15 (dd, J = 14.7, 4.1 Hz,
1H), 2.00−1.91 (m, 1H), 1.53 (td, J = 13.0, 8.8 Hz, 1H), 1.38 (d, J =
6.7 Hz, 3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 214.9, 187.3,
186.7, 161.2, 156.5, 156.0, 135.9, 135.7, 134.4, 133.9, 121.0, 120.0,
118.5, 111.6, 111.4, 100.3, 76.6, 71.4, 69.0, 68.3, 65.8, 60.1, 56.8, 43.0,
36.0, 33.9, 29.0, 18.7. HRMS (ESI) m/z: [M + H+] calcd for
C29H35NO11: 572.2126; found 572.2131.
13C{1H}-GATED NMR
(chloroform-d, 126 MHz) δ 100.31 (JC1′, H1′ = 169 Hz, C-1).
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.joc.1c00220.
Biological evaluation of the panel of (N,N-dimethyl)-
doxorubicin glycosyl diastereomers as well as 1H, 13C,
COSY, and HSQC NMR data for compounds 2a/b−
4a/b and intermediates in their synthesis (PDF)
■ AUTHOR INFORMATION
Corresponding Authors
Jacques J. C. Neefjes − ONCODE Institute, Leiden University
Medical Center, 2333 ZC Leiden, The Netherlands;
Email: j.j.c.neefjes@lumc.nl
Jeroen D. C. Codée − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands; orcid.org/
0000-0003-3531-2138; Email: jcodee@chem.leidenuniv.nl
Authors
Dennis P. A. Wander − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands; orcid.org/
0000-0003-3881-5240
Sabina Y. van der Zanden − ONCODE Institute, Leiden
University Medical Center, 2333 ZC Leiden, The
Netherlands
Merijn B. L. Vriends − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands
Branca C. van Veen − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands
Joey G. C. Vlaming − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands
Thomas Bruyning − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands
Thomas Hansen − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands; Department
of Theoretical Chemistry, Amsterdam Institute of Molecular
and Life Sciences (AIMSS), Amsterdam Center for Multiscale
Modeling (ACMM), Vrije Universiteit Amsterdam, 1081 HV
Amsterdam, The Netherlands; orcid.org/0000-0002-
6291-1569
Gijsbert A. van der Marel − Leiden Institute of Chemistry,
Leiden University, 2333 CC Leiden, The Netherlands
Herman S. Overkleeft − Leiden Institute of Chemistry, Leiden
University, 2333 CC Leiden, The Netherlands
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.joc.1c00220
Author Contributions
∥D.P.A.W. and S.Y.v.d.Z. contributed equally to this work.
Funding
This work was supported by grants from the Dutch Cancer
Society KWF (JN) and by the Institute for Chemical
Immunology, an NWO Gravitation project funded by the
Ministry of Education, Culture and Science of the Netherlands
to HO and JN.
Notes
The authors declare the following competing financial
interest(s): J. Neefjes is a shareholder in NIHM, that aims
to produce aclarubicin for clinical use.
■ REFERENCES
(1) Grand View Research. Doxorubicin Market by Application
(Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma,
Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) and Segment
Forecasts, 2018−2024, 2016.
(2) Lefrak, E. A.; Pit’ha, J.; Rosenheim, S.; Gottlieb, J. A. A
Clinicopathologic Analysis of Adriamycin Cardiotoxicity. Cancer
1973, 32, 302−314.
(3) Krohn, K. In Anthracycline Chemistry and Biology I Biological
Occurence and Biosynthesis, Synthesis and Chemistry; Balzani, V.; de
Meijere, A.; Houk, K. N.; Kessler, H.; Lehn, J.-M.; Ley, S. V.;
The Journal of Organic Chemistry pubs.acs.org/joc Article
https://doi.org/10.1021/acs.joc.1c00220
J. Org. Chem. 2021, 86, 5757−5770
5769
Schreiber, S. L.; Thiem, J.; Trost, B. M.; Vögtle, F.; Yamamoto, H.,
Eds.; Springer Verlag, 2008.
(4) Weiss, R. B. The Anthracyclines: Will We Ever Find a Better
Doxorubicin? Semin. Oncol. 1992, 19, 670−686.
(5) Booser, D. J.; Hortobagyi, G. N. Anthracycline Antibiotics in
Cancer Therapy. Drugs 1994, 47, 223−258.
(6) Mele, D.; Nardozza, M.; Spallarossa, P.; Frassoldati, A.;
Tocchetti, C. G.; Cadeddu, C.; Madonna, R.; Malagu,̀ M.; Ferrari,
R.; Mercuro, G. Current Views on Anthracycline Cardiotoxicity. Heart
Fail. Rev. 2016, 21, 621−634.
(7) Launchbury, A. P.; Habboubi, N. Epirubicin and Doxorubicin: A
Comparison of Their Characteristics, Therapeutic Activity and
Toxicity. Cancer Treat. Rev. 1993, 19, 197−228.
(8) Nitiss, J. L. Targeting DNA Topoisomerase II in Cancer
Chemotherapy. Nat. Rev. Cancer 2009, 9, 338−350.
(9) Pang, B.; Qiao, X.; Janssen, L.; Velds, A.; Groothuis, T.;
Kerkhoven, R.; Nieuwland, M.; Ovaa, H.; Rottenberg, S.; van
Tellingen, O.; Janssen, J.; Huijgens, P.; Zwart, W.; Neefjes, J. Drug-
Induced Histone Eviction from Open Chromatin Contributes to the
Chemotherapeutic Effects of Doxorubicin. Nat. Commun. 2013, 4,
No. 1908.
(10) Qiao, X.; van der Zanden, S. Y.; Wander, D. P. A.; Borras̀, D.
M.; Song, J.-Y.; Li, X.; van Duikeren, S.; van Gils, N.; Rutten, A.; van
Herwaarden, T.; van Tellingen, O.; Giacomelli, E.; Bellin, M.; Orlova,
V.; Tertoolen, L. G. J.; Gerhardt, S.; Akkermans, J. J.; Bakker, J. M.;
Zuur, C. L.; Pang, B.; Smits, A. M.; Mummery, C. L.; Smit, L.; Arens,
R.; Li, J.; Overkleeft, H. S.; Neefjes, J. Uncoupling DNA Damage from
Chromatin Damage to Detoxify Doxorubicin. Proc. Natl. Acad. Sci.
U.S.A. 2020, 117, 15182−15192.
(11) Yang, F.; Kemp, C. J.; Henikoff, S. Doxorubicin Enhances
Nucleosome Turnover around Promoters. Curr. Biol. 2013, 23, 782−
787.
(12) Pang, B.; de Jong, J.; Qiao, X.; Wessels, L. F. A.; Neefjes, J.
Chemical Profiling of the Genome with Anti-Cancer Drugs Defines
Target Specificities. Nat. Chem. Biol. 2015, 11, 472−480.
(13) Wander, D. P. A.; van der Zanden, S. Y.; van der Marel, G. A.;
Overkleeft, H. S.; Neefjes, J.; Codée, J. D. C. Doxorubicin and
Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer
Agents. J. Med. Chem. 2020, 63, 12814−12829.
(14) Kulikowski, T.; Bretner, M.; Najda, A.; Cova, L. New
Derivatives of Epirubicin, Their Medicinal Application and
Pharmaceuticaly Acceptable Forms of Drugs. WO2007/075094A1,
2006.
(15) Arlandini, E.; Vigevani, A.; Arcamone, F. Interaction of New
Derivatives of Daunorubicin and Doxorubicin with DNA. Part II.
Farm. Ed. Sci. 1980, 35, 65−78.
(16) Yu, B. Gold(I)-Catalyzed Glycosylation with Glycosyl o-
Alkynylbenzoates as Donors. Acc. Chem. Res. 2018, 51, 507−516.
(17) Wander, D. P. A. Understanding Anthracyclines: Synthesis of a
Focused Library of Doxorubicin/AclarubicinInspired Structures;
Leiden University, 2019.
(18) Fan, E.; Shi, W.; Lowary, T. L. Synthesis of Daunorubicin
Analogues Containing Truncated Aromatic Cores and Unnatural
Monosaccharide Residues. J. Org. Chem. 2007, 72, 2917−2928.
(19) Noshita, T.; Sugiyama, T.; Kitazumi, Y.; Oritani, T.
Reinvestigation of Phenolic Ferrier Reaction: Selective Synthesis of
Aryl O-Δ 2 -Glycosides. Biosci., Biotechnol., Biochem. 1995, 59, 2052−
2055.
(20) Ma, Y.; Li, Z.; Shi, H.; Zhang, J.; Yu, B. Assembly of Digitoxin
by Gold(I)-Catalyzed Glycosidation of Glycosyl o-Alkynylbenzoates.
J. Org. Chem. 2011, 76, 9748−9756.
(21) Renneberg, B.; Li, Y.-M.; Laatsch, H.; Fiebig, H.-H. A Short
and Efficient Transformation of Rhamnose into Activated Daunos-
amine, Acosamine, Ristosamine and Epi-Daunosamine Derivatives,
and Synthesis of an Anthracycline Antibiotic Acosaminyl-ε-Iso-
Rhodomycinone. Carbohydr. Res. 2000, 329, 861−872.
(22) Horton, D.; Weckerle, W. A Preparative Synthesis of 3-Amino-
2,3,6-Trideoxy-l-Lyxo-Hexose (Daunosamine) Hydrochloride from d-
Mannose. Carbohydr. Res. 1975, 44, 227−240.
(23) The stereochemical outcome of the glycosylations indicates
that long-range participation of the N-Alloc group does not play a
significant role in the studied glycosylations (a) Hansen, T.; Elferink,
H.; van Hengst, J. M. A.; Houthuijs, K. J.; Remmerswaal, W. A.;
Kromm, A.; Berden, G.; van der Vorm, S.; Rijs, A. M.; Overkleeft, H.
S.; Filippov, D. V.; Rutjes, F. P. J. T.; van der Marel, G. A.; Martens, J.;
Oomens, J.; Codée, J. D. C.; Boltje, T. J. Characterization of Glycosyl
Dioxolenium Ions and Their Role in Glycosylation Reactions. Nat.
Commun. 2020, 11, No. 2664. (b) Komarova, B. S.; Tsvetkov, Y. E.;
Nifantiev, N. E. Design of α-Selective Glycopyranosyl Donors Relying
on Remote Anchimeric Assistance. Chem. Rec. 2016, 16, 488−506.
(24) Tang, Y.; Li, J.; Zhu, Y.; Li, Y.; Yu, B. Mechanistic Insights into
the Gold(I)-Catalyzed Activation of Glycosyl Ortho-Alkynylbenzoates
for Glycosidation. J. Am. Chem. Soc. 2013, 135, 18396−18405.
(25) Hansen, T.; Lebedel, L.; Remmerswaal, W. A.; van der Vorm,
S.; Wander, D. P. A.; Somers, M.; Overkleeft, H. S.; Filippov, D. V.;
Désiré, J.; Mingot, A.; Bleriot, Y.; van der Marel, G. A.; Thibaudeau,
S.; Codée, J. D. C. Defining the SN1 Side of Glycosylation Reactions:
Stereoselectivity of Glycopyranosyl Cations. ACS Cent. Sci. 2019, 5,
781−788.
(26) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. Stereo-
chemical Reversal of Nucleophilic Substitution Reactions Depending
upon Substituent: Reactions of Heteroatom-Substituted Six-Mem-
bered-Ring Oxocarbenium Ions through Pseudoaxial Conformers. J.
Am. Chem. Soc. 2000, 122, 168−169.
(27) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.;
Woerpel, K. A. Stereochemistry of Nucleophilic Substitution
Reactions Depending upon Substituent: Evidence for Electrostatic
Stabilization of Pseudoaxial Conformers of Oxocarbenium Ions by
Heteroatom Substituents. J. Am. Chem. Soc. 2003, 125, 15521−15528.
(28) Zeng, J.; Sun, G.; Yao, W.; Zhu, Y.; Wang, R.; Cai, L.; Liu, K.;
Zhang, Q.; Liu, X.-W.; Wan, Q. 3-Aminodeoxypyranoses in
Glycosylation: Diversity-Oriented Synthesis and Assembly in
Oligosaccharides. Angew. Chem., Int. Ed. 2017, 56, 5227−5231.
(29) Bartner, P.; Boxler, D. L.; Brambilla, R.; Mallams, A. K.;
Morton, J. B.; Reichert, P.; Sancilio, F. D.; Surprenant, H.; Tomalesky,
G.; Lukacs, G.; Olesker, A.; Thang, T. T.; Valente, L.; Omura, S. The
Megalomicins. Part 7. A Structural Revision by Carbon-13 Nuclear
Magnetic Resonance and X-Ray Crystallography. Synthesis and
Conformational Analysis of 3-Dimethylamino- and 3-Azido-D- and
-L-Hexopyranosides, and the Crystal Structure of 4″-O-(4-Iodobe. J.
Chem. Soc., Perkin Trans. 1 1979, 1600−1624.
(30) Kuo, L. J.; Yang, L. X. γ-H2AX-A Novel Biomaker for DNA
Double-Strand Breaks. In Vivo 2008, 305−309.
(31) Olive, P. L.; Wlodek, D.; Banáth, J. P. DNA Double-Strand
Breaks Measured in Individual Cells Subjected to Gel Electrophoresis.
Cancer Res. 1991, 51, 4671−4676.
The Journal of Organic Chemistry pubs.acs.org/joc Article
https://doi.org/10.1021/acs.joc.1c00220
J. Org. Chem. 2021, 86, 5757−5770
5770
